Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.68 |
| ▸ | CTSL | P07711 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | MYC | P01106 | 1/20 | 0.64 |
| ▸ | MAX | P61244 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030579 | 0.89 | CTSV (0.77) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL9000255 | 0.84 | FABP3 (0.61) | MAPTGAAAKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL22720195 | 0.84 | CTSV (0.78) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL6035244 | 0.82 | CTSV (0.60) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL22720188 | 0.82 | MAPT (0.74) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL22720190 | 0.82 | CTSV (0.68) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL10531270 | 0.82 | CTSV (0.68) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL6141339 | 0.82 | CTSV (0.76) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL4249101 | 0.82 | CTSV (0.86) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL21248515 | 0.82 | AKR1C3 (0.69) | CTSVCTSLMAPTMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545651-B2 | Diphenylamine-linked chiral bis(oxazoline) ligand without C2-symmetry, synthesis method and application thereof | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2026-02-10 | — | — | US | disclosed |
| US-20220227719-A1 | A diphenylamine-linked chiral bis(oxazoline) ligand without C2-symmetry, synthesis method and application thereof | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2022-07-21 | — | — | US | disclosed |
| CN-110229114-B | Remove C2-toSymmetric diphenylamine type chiral bisoxazoline ligand and synthetic method and application thereof | 浙江工业大学 | 2021-07-27 | — | — | CN | disclosed |
| WO-2020238559-A1 | DE-C2-SYMMETRIC DIPHENYLAMINE-TYPE CHIRAL BISOXAZOLINE LIGAND, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 浙江工业大学 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227719-A1 | A diphenylamine-linked chiral bis(oxazoline) ligand without C2-symmetry, synthesis method and application thereof | AOC1, AOC2, AOC3 | CTSV 3526/4885CTSL 3990/4885MAPT 3073/4885 |
| US-12545651-B2 | Diphenylamine-linked chiral bis(oxazoline) ligand without C2-symmetry, synthesis method and application thereof | AOC2, AOC1, AOC3 | CTSV 4064/4885CTSL 4552/4885MAPT 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.